Compare · NAOV vs STE
NAOV vs STE
Side-by-side comparison of NanoVibronix Inc. (NAOV) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAOV and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $20.72B, about 926.8x NAOV ($22.4M).
- Over the past year, NAOV is down 51.6% and STE is down 12.9% - STE leads by 38.7 points.
- STE has hit the wire 28 times in the past 4 weeks while NAOV has been quiet.
- STE has more recent analyst coverage (16 ratings vs 0 for NAOV).
- Company
- NanoVibronix Inc.
- STERIS plc (Ireland)
- Price
- $4.67+5.30%
- $212.24+0.93%
- Market cap
- $22.4M
- $20.72B
- 1M return
- -3.31%
- -0.46%
- 1Y return
- -51.58%
- -12.85%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 28
- Recent ratings
- 0
- 16
NanoVibronix Inc.
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest NAOV
- ENvue Medical Strengthens Patent Portfolio with New USPTO Notice of Allowance for Feeding Tube Combining Electromagnetic Navigation with Direct Visualization Through an Integrated Internal Camera
- ENvue Medical Signs Strategic Partnership Agreement with U-Deliver for U.S. Distribution of Over-the-Counter Reusable ENFit Syringe Line
- ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial
- ENvue Medical Launches Over-the-Counter Reusable ENFit Syringes to Support Feeding and Medication Delivery without a Prescription
- ENvue Medical Launches Program to Address Patient Pain and Discomfort with Indwelling Nasogastric Tubes Based on Previously Published, Peer-Reviewed Clinical Research
- ENvue Medical to Ring the Nasdaq Opening Bell on Wednesday, January 14th, 2026
- SEC Form 3 filed by new insider Pionati Pellegrino
- SEC Form 3 filed by new insider Johnson David Ian
- SEC Form 424B3 filed by NanoVibronix Inc.
- ENvue Medical, Formerly NanoVibronix, UroShield® Kit Secures Reimbursement in the UK
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam was granted 4,359 units of Ordinary Shares and covered exercise/tax liability with 247 units of Ordinary Shares, increasing direct ownership by 12% to 37,444 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato was granted 750 units of Ordinary Shares and covered exercise/tax liability with 41 units of Ordinary Shares, increasing direct ownership by 13% to 6,323 units (SEC Form 4)
- SVP and President, Healthcare Majors Cary L was granted 4,746 units of Ordinary Shares and covered exercise/tax liability with 67 units of Ordinary Shares, increasing direct ownership by 37% to 17,338 units (SEC Form 4)
- VP, Chf. Comp. & Quality Offc. Mcgowan Lindsey covered exercise/tax liability with 329 units of Ordinary Shares and was granted 1,155 units of Ordinary Shares, increasing direct ownership by 17% to 5,656 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia was granted 2,316 units of Ordinary Shares and covered exercise/tax liability with 127 units of Ordinary Shares, increasing direct ownership by 21% to 12,691 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare was granted 3,009 units of Ordinary Shares and covered exercise/tax liability with 591 units of Ordinary Shares, increasing direct ownership by 20% to 14,627 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E was granted 2,199 units of Ordinary Shares and covered exercise/tax liability with 66 units of Ordinary Shares, increasing direct ownership by 22% to 11,666 units (SEC Form 4)
- President and CEO Carestio Daniel A was granted 23,736 units of Ordinary Shares and covered exercise/tax liability with 995 units of Ordinary Shares, increasing direct ownership by 46% to 72,583 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L was granted 5,325 units of Ordinary Shares, increasing direct ownership by 64% to 13,464 units (SEC Form 4)
- SEC Form 4 filed by Director Boulud Pierre